Long-term Follow-up of Depressive Disorders in Psychiatric Care

Conditions studied

Depression, Psychiatric Diagnosis, Personality Disorders, Suicide, Attempted, CYP2D6 Polymorphism, Anhedonia

About this study

The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care. The current patient cohort was collected in 2012-2021 in the study "Pharmacogenetics in patients with depression with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6". The cohort consists of 415 patients, examined carefully regarding diagnostic assessment and earlier treatment. All participants were also genotyped for the drug metabolizing enzymes CYP2D6 and CYP2C19. Blood samples were stored in biobank for other analyses linked to prognostic markers. The patient cohort will now be followed up with a review of medical records and extraction of register data for a period of 5 years after their participation in the original study. The purpose of the study is to improve treatment and increase knowledge about long-term prognosis in difficult-to-treat depression. This is done by examining symptom profiles, monitoring clinical course and suicidality, and examining prognostic markers.

Interventions

• Other: No intervention is used. — No intervention is used.

Primary outcomes

• Suicide attempt and suicide (5 years follow-up after baseline visit.)
• Clinical course of depression (5 years follow-up after baseline visit)
• Comparison of diagnostic assessment for personality disorders (Baseline data and 5 years follow-up from inclusion.)
• Course and diagnostic characteristics of bipolar disorder (Baseline data and 5 years follow-up after inclusion.)
• Results from pharmacological counseling for CYP2D6UM och CYP2D6PM (Nine weeks of pharmacological counseling after baseline and 5 years follow-up from baseline visit)
• Prediction of long-term prognosis of depressive symptom profiles (5 years follow-up from baseline visit)
• Course of disease related to dopamine D3 receptor and other biomarkers (5 years follow-up from baseline visit)

Eligibility information

Study locations

• Psychiatry Reserach Unit, Lund, 221 85 Sweden
• Research Unit, Office of Psychiatricy, habilitation and technical aid, Lund, 221 85 Sweden